Table 4 Mean ± standard deviation VASI score for vitiligo type and lesion location at 6 months after the start of treatment compared among the placebo, monotherapy and combination therapy groups (ITT analysis).

From: The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study

Type and location

n

Placebo

Bimatoprost 0.01% monotherapy

Bimatoprost

0.01% + NBUVB

p*

Type of vitiligo

 Non-segmental type

13

93.09 ± 9.3

70.77 ± 23.6

53.85 ± 27.8

 < 0.001a,b

 Segmental type

6

83.33 ± 36.1

68.33 ± 34.2

60.00 ± 26.5

0.490

Location of lesion

 Face and neck

8

80.63 ± 29.6

69.38 ± 25.6

53.13 ± 20.9

0.178

 Other areas

11

96.82 ± 7.8

70.45 ± 28.2

57.73 ± 31.3

 < 0.001a,b

  1. A p-value < 0.05 indicates statistical significance.
  2. VASI score Vitiligo Area Scoring Index score, NBUVB narrowband ultraviolet B phototherapy, ITT intention to treat.
  3. *Repeated measures analysis of variance (ANOVA) with multiple comparisons by Bonferroni method.
  4. aPlacebo vs. monotherapy.
  5. bPlacebo vs. combination therapy.
Back to article page